2. Search Result
Search Result
Results for "

HT-29cell

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

1

Peptides

14

Natural
Products

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139206
    LY3509754
    4 Publications Verification

    IL-17A inhibitor 1

    		 Interleukin Related Inflammation/Immunology
    LY3509754 (IL-17A inhibitor 1) is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells .
    LY3509754
  • HY-12855A
    Lys05
    4 Publications Verification

    Lys01 trihydrochloride

    		 Autophagy Cancer
    Lys05 (Lys01 trihydrochloride) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.
    Lys05
  • HY-101524
    TC13172
    3 Publications Verification

    		 Mixed Lineage Kinase Cancer
    TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC50 value of 2 nM for HT-29 cells .
    TC13172
  • HY-13734
    PX-12
    Maximum Cited Publications
    12 Publications Verification

    IV-2

    		 Apoptosis Cancer
    PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1 (Trx-1); inhibits the growth of MCF-7 and HT-29 cells with IC50 values of 1.9 and 2.9 μM, respectively.
    PX-12
  • HY-14444
    Plinabulin
    2 Publications Verification

    NPI-2358

    		 Microtubule/Tubulin Cancer
    Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells . Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells .
    Plinabulin
  • HY-107664
    SR 142948

    		Neurotensin Receptor Neurological Disease
    SR 142948 is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 shows blood-brain permeability and can be used in study of psychiatric disorders .
    SR 142948
  • HY-N7085
    Citropten

    5,7-Dimethoxycoumarin; Limettin

    		 Environmental Pollutants ERK p38 MAPK JNK Neurological Disease Inflammation/Immunology Cancer
    Citropten (5, 7-dimethoxycoumarin) is one of the coumarin derivatives. Citropten is an effective oral anticancer agent. Citropten has anti-proliferative activity against A2058 and B16 melanoma cells. Citropten exerts anti-inflammatory effects through the NFκB and MAPK signaling pathways. Citropten acts as an antidepressant through heat shock protein-70, monoamine oxidase-A and inhibition of apoptosis .
    Citropten
  • HY-N6002
    3'-Hydroxypterostilbene
    1 Publications Verification

    		 Apoptosis Autophagy Cancer
    3'-Hydroxypterostilbene is a Pterostilbene (HY-N0828) analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC50s of 9.0, 40.2 and 70.9 μM, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer .
    3'-Hydroxypterostilbene
  • HY-126779
    Stictic acid

    		Fungal Cancer
    Stictic acid is a secondary metabolite that can be isolated from the lichen Lobaria pulmonaria (L.) Hoffm. Stictic acid inhibits growth of human colon adenocarcinoma HT-29 cells (IC50: 29.29 μg/mL) .
    Stictic acid
  • HY-159795
    Claturafenib

    PF-07799933; ARRY-440

    		 Raf PERK Cancer
    Claturafenib ( PF-07799933) is an orally active inhibitor of pan-mutant BRAF. Claturafenib inhibits pERK in cells (IC50 value of 1.6 nM in HT29 cells). Claturafenib has anticancer activity against BRAF G469A mutant NSCLC and BRAF K601E mutant melanoma .
    Claturafenib
  • HY-130602
    MS432

    		PROTACs MEK Cancer
    MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2. MS432 displays good plasma exposure in mice, exhibiting DC50 values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively .
    MS432
  • HY-149302
    MC4033
    1 Publications Verification

    		 Apoptosis Autophagy Histone Acetyltransferase Cancer
    MC4033 shows IC50s of 39.4 μM, 52.1 μM, 41 μM and 30.1 μM in HCT116, H1299, A549 and U937, respectively .
    MC4033 (25, 50, 100, and 200 μM, 72 h) reduces the level of H4K16Ac in HT29 cells, suggesting its ability to inhibit KAT8 in cells .
    MC4033
  • HY-75564
    Cyclo(Ala-Gly)

    		Endogenous Metabolite Cancer
    Cyclo(Ala-Gly), a metabolite of a mangrove endophytic fungus, Penicillium thomi, exhibits cytotoxicity against A549, HepG2 and HT29 cells. The IC50 values range from 9.5 to 18.1 μM .
    Cyclo(Ala-Gly)
  • HY-120528A
    GB-110 hydrochloride
    1 Publications Verification

    		 Protease Activated Receptor (PAR) Inflammation/Immunology Cancer
    GB-110 hydrochloride is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110 hydrochloride selectively induces PAR2-mediated intracellular Ca 2+ release in HT29 cells with an EC50 of 0.28 μM .
    GB-110 hydrochloride
  • HY-13620
    Elinafide

    LU 79553

    		 Topoisomerase Cancer
    Elinafide is an anticancer agent with a naphthalimide structure that targets DNA. Elinafide interferes with cell metabolism by inserting a planar ring into the DNA double helix and interacting with enzymes through its side chain.LU-79553 is a DNA-binding topoisomerase II inhibitor. The IC50 value of Elinafide for HT-29 cells is 0.014 μM .
    Elinafide
  • HY-176279
    Hsp90-IN-42

    		HSP Cancer
    Hsp90-IN-42 (Compound 13l) is a potent heat shock protein 90 (Hsp90) inhibitor (IC50=15.65 nM). Hsp90-IN-42 reduces the stability of the epidermal growth factor receptor (EGFR), suppressing the activation of the EGFR-Akt signaling pathway, inducing G0/G1 phase arrest in colorectal cancer cells (such as HT-29 cells), and slightly triggering apoptosis. Hsp90-IN-42 also inhibits cell proliferation and migration by down-regulating the expression of CDK12, CDK13, and Bcl-2 proteins, and up-regulating the expression of Bax protein. Hsp90-IN-42 is promising for research of colorectal cancer .
    Hsp90-IN-42
  • HY-107664A
    SR 142948 dihydrochloride

    		Neurotensin Receptor Neurological Disease
    SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders .
    SR 142948 dihydrochloride
  • HY-174448
    WEE1-IN-12

    		Wee1 Cancer
    WEE1-IN-12 (Compound 87) is a Wee1 kinase inhibitor with an IC50 of 2.0 nM. WEE1-IN-12 can inhibit the proliferation of HT29 cells (IC50: 1.07 μM), and when used in combination with Gemcitabine (HY-17026), the effect is better (IC50: 0.34 μM). WEE1-IN-12 can be used in the research of tumors such as colon cancer .
    WEE1-IN-12
  • HY-107664B
    SR 142948 TFA

    		Neurotensin Receptor Neurological Disease
    SR 142948 TFA is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 TFA antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 TFA blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 TFA shows blood-brain permeability and can be used in study of psychiatric disorders .
    SR 142948 TFA
  • HY-B1714
    NSC 601980 analog

    		Drug Derivative Cancer
    NSC 601980 analog is an analogue of NSC601980. In yeast screening experiments, NSC 601980 exhibited antitumor activity, effectively inhibiting cell proliferation in both COLO 205 and HT29 cell lines, with Log GI 50 values of -6.6 and -6.9, respectively.
    NSC 601980 analog
  • HY-N8934
    6β-Hydroxytomentosin

    		Others Cancer
    6β-Hydroxytomentosin, a sesquiterpenoid, can be found in flowers of Inula japonica. 6β-Hydroxytomentosin exhibits weak cytotoxicities against A549, SK-OV-3, HepG-2 and HT-29 cell lines .
    6β-Hydroxytomentosin
  • HY-120528
    GB-110

    		Protease Activated Receptor (PAR) Inflammation/Immunology Cancer
    GB-110 is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110 selectively induces PAR2-mediated intracellular Ca 2+ release in HT29 cells with an EC50 of 0.28 μM .
    GB-110
  • HY-149952
    ATR-IN-23

    		ATM/ATR Cancer
    ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .
    ATR-IN-23
  • HY-N1631
    1-Hydroxyrutecarpine

    1-Hydroxyrutaecarpine

    		 Drug Derivative Others
    1-Hydroxyrutaecarpine (compound 1a) is a hydroxy-derivative of rutaecarpine. 1-Hydroxyrutaecarpine shows cytotoxicities with ED50s of 3.72, 7.44 µg/mL for P-388 and HT-29 cells, respectively. 1-Hydroxyrutaecarpine shows antiplatelet activity .
    1-Hydroxyrutecarpine
  • HY-178511
    KIF18A-IN-17

    		Kinesin Cancer
    KIF18A-IN-17 (Example 37A) is a KIF18A inhibitor with racemic form with an IC50 of 48 nM. KIF18A-IN-17 exhibits anti-proliferative activity against HT29 cells. KIF18A-IN-17 can be used for the study of cancers such as breast cancer and ovarian cancer .
    KIF18A-IN-17
  • HY-157740
    XSJ-10

    		HDAC Cancer
    XSJ-10 is a HDAC inhibitor containing a RAS/RAF protein interfering unit, with IC50s of 0.05 and 0.04 μM in PANC-1 cells and HT-29 cells. XSJ-10 can effectively induce the apoptosis of cancer cells and suppress the tumor by strongly inhibiting the RAS-RAF-MEK-ERK signaling pathway and the acetylation level of HDAC3 .
    XSJ-10
  • HY-151542
    MLKL-IN-4

    		Mixed Lineage Kinase Necroptosis RIP kinase Neurological Disease
    MLKL-IN-4 (compound 56) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC50 of 82 nM . MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MLKL-IN-4
  • HY-N1655
    2,3-Dihydroamentoflavone 7,4'-dimethyl ether

    		Others Cancer
    2,3-Dihydroamentoflavone 7,4'-dimethyl ether is a biflavonoid, which can be isolated from the aerial parts of Selaginella delicatula. 2,3-Dihydroamentoflavone 7,4'-dimethyl ether exhibits cytotoxicities against P-388 and HT-29 cell lines, with ED50 (median effective dose) values of 3.50 and 5.25 µg/mL, respectively .
    2,3-Dihydroamentoflavone 7,4'-dimethyl ether
  • HY-151541
    MLKL-IN-3

    		Mixed Lineage Kinase Necroptosis Neurological Disease
    MLKL-IN-3 (compound 66) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-3 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC50 of 31 nM . MLKL-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MLKL-IN-3
  • HY-175540
    PDGFRα kinase-IN-2

    		PDGFR Cardiovascular Disease Cancer
    PDGFRα kinase-IN-2 is a potent PDGFR-α inhibitor with an IC50 of 2.1 nM. PDGFRα kinase-IN-2 exhibits anticancer activity against human colon cancer HT-29 cell with an IC50 of 1.48 μM. PDGFRα kinase-IN-2 has anti-angiogenic activity in zebrafish models and low embryonic lethality. PDGFRα kinase-IN-2 can used for the studies of colon cancer and anti-angiogenesis .
    PDGFRα kinase-IN-2
  • HY-173124
    CDK2/FLT4/PDGFRA-IN-1

    		CDK VEGFR PDGFR Apoptosis Cancer
    CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells .
    CDK2/FLT4/PDGFRA-IN-1
  • HY-14909R
    Bardoxolone (Standard)

    CDDO (Standard); RTA 401 (Standard)

    		 Keap1-Nrf2 Necroptosis SARS-CoV Virus Protease Reference Standards Infection Cardiovascular Disease Inflammation/Immunology
    Bardoxolone (Standard) is the analytical standard of Bardoxolone (HY-14909). This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury .
    Bardoxolone (Standard)
  • HY-120339
    STK899704

    		Microtubule/Tubulin FAK MEK ERK MMP Caspase PARP Apoptosis MDM-2/p53 Cancer
    STK899704 is a tubulin polymerization inhibitor. STK899704 exhibits broad-spectrum inhibitory activity against various cancer cell lines with IC50 values ​​ranging from 0.2 to 1.0 μM. STK899704 disrupts the mitotic spindle structure, inducing G2/M phase cell cycle arrest. STK899704 inhibits the migration ability of HT29 cells by downregulating the FAK-MEK-ERK signaling pathway, thereby suppressing the expression and activity of MMP-2 and MMP-9. STK899704 activates caspase-3/7/8/9, leading to PARP cleavage and inducing apoptosis. STK899704 induces cellular senescence through the p53 pathway. STK899704 can be used in research on skin cancer, lung cancer, colon cancer, and other cancers .
    STK899704
  • HY-139062
    C6 Urea Ceramide

    C6 Ceramide (d18:1/6:0) Urea; Cer(d18:1/6:0) Urea; D-erythro-Urea-C6-Ceramide

    		 Apoptosis Ceramidase Autophagy β-catenin Cancer
    C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.
    C6 Urea Ceramide
  • HY-160170
    Necrosis inhibitor 3

    		Necroptosis Cancer
    Necrosis inhibitor 3 (compound B3) is a poteng inhibitor of necrosis, with the IC50 value of 0.29 nM in HT29 cells .
    Necrosis inhibitor 3
  • HY-161361
    MLKL-IN-7

    		Mixed Lineage Kinase Cancer
    MLKL-IN-7 (compound 9) is a MLKL inhibitor, and shows anti-necroptosis activity in HT-29 cells with the IC50 of 148.4 nM .
    MLKL-IN-7
  • HY-123707
    KPU-300

    		Microtubule/Tubulin Cancer
    KPU-300 (compound 6b) is a tubulin inhibitor. KPU-300 has potent cytotoxicity with an IC50 value of 7.0 nM against HT-29 cells .
    KPU-300
  • HY-W928623
    2-Acetylthiophene thiosemicarbazone

    ATTSC

    		 Bacterial Infection Cancer
    2-Acetylthiophene thiosemicarbazone is an antibacterial agent. 2-Acetylthiophene thiosemicarbazone exhibits anticancer activity, with an IC50 value of 8.6 μM against HT-29 cells .
    2-Acetylthiophene thiosemicarbazone
  • HY-169735
    Aurora A inhibitor 4

    		Aurora Kinase Cancer
    Aurora A inhibitor 4 (compound C9) is a potent inhibitor of Aurora A, with the GI50 of 4.26 and 7.08 μM in DU 145 cells and HT-29 cells, respectively .
    Aurora A inhibitor 4
  • HY-B1714A
    NSC 601980

    		Drug Derivative Cancer
    NSC 601980 is an anti-tumor compound. In yeast screening experiments, NSC 601980 inhibits cell proliferation in COLO205 and HT29 cell lines with LogGI50 of -6.6 and -6.9, respectively.
    NSC 601980
  • HY-N3123
    Oxychelerythrine

    Dihydrooxochelerythrine

    		 Others Cancer
    Oxychelerythrine is an alkaloid that can be isolated from Zanthoxylum integrifoliolum. Oxychelerythrine exhibits cytotoxicity against P-388 and HT-29 cell lines with ED50s of 3.25 and 5.48 μg/mL, respectively .
    Oxychelerythrine
  • HY-146274
    c-Met-IN-10

    		c-Met/HGFR Apoptosis Cancer
    c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC50 value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC50s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer .
    c-Met-IN-10
  • HY-157963
    RIPK1-IN-23

    		RIP kinase Necroptosis Inflammation/Immunology Cancer
    RIPK1-IN-23 (compound 19) is a RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities .
    RIPK1-IN-23
  • HY-173445
    RIPK1-IN-30

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-30 (compound 24) is a potent RIPK1 inhibitor with an IC50 of 2.01 μM. RIPK1-IN-30 exhibits protective effects in HT-29 cell model of TSZ-induced necroptosis with an EC50 of 6.77 μM .
    RIPK1-IN-30
  • HY-115949
    Antitumor agent-47

    		HSP Cancer
    Antitumor agent-47 (Compound 3e) is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC50 values of 8.07 µM and 6.27 µM, respectively .
    Antitumor agent-47
  • HY-N8387
    Neogrifolin

    		Ras Cancer
    Neogrifolin is an inhibitor of KRAS. Neogrifolin suppress KRAS expression in human colon cancer cells. Neogrifolin has anti-cell viability activity against HeLa, SW480 and HT29 cells wih IC50s of 24.3, 34.6, and 30.1 μM, respectively .
    Neogrifolin
  • HY-173227
    TrkC-IN-1

    		Trk Receptor Cancer
    TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC. The IC50 values for EBC-1 and HT-29 cells are 3.3-7.1 and 7.3-10.2 μΜ, respectively. TrkC-IN-1 is expected to be used in the research of the anti-cancer field .
    TrkC-IN-1
  • HY-N8462
    6-O-Nicotinoylscutebarbatine G

    Scutebatin C

    		 Others Cancer
    6-O-Nicotinoylscutebarbatine G is an alkaloid that can be isolated from Scutellaria barbata.6-O-Nicotinoylscutebarbatine has cytotoxic activities against HONE-1, KB and HT29 cells with IC50s of 3.1, 2.1 and 5.7 μM, respectively .
    6-O-Nicotinoylscutebarbatine G
  • HY-163806
    NT376

    		HDAC Neurological Disease Cancer
    NT376 is a high potency and selectivity inhibitor of class-IIa Histone deacetylases (HDAC) with an IC50 value of 32 nM, similar to NT160 (HY-149285) (IC50= 46 nM) in HT-29 cells. NT376 is proming for research of various cancers and in the diseases of the central nervous system (CNS) such as Alzheimer’s and Huntington’s diseases .
    NT376
  • HY-N14415
    Cochleamycin A

    		Bacterial Infection Cancer
    Cochleamycin A showed strong inhibitory activity against tumor cells, with IC50s (μg/mL) of P388, HL60, K562, COL0205 and HT29 cells of 1.6, 14.0, 6.2, 16.5 and 19.1, respectively. Cochleamycin A also has anti-Gram-positive bacteria activity .
    Cochleamycin A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: